These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 33301960)
1. Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic. Desborough R; Nicklin P; Gossiel F; Balasubramanian M; Walsh JS; Petryk A; Teynor M; Eastell R Bone; 2021 Mar; 144():115795. PubMed ID: 33301960 [TBL] [Abstract][Full Text] [Related]
2. Bone mineral density and fracture risk in adult patients with hypophosphatasia. Genest F; Claußen L; Rak D; Seefried L Osteoporos Int; 2021 Feb; 32(2):377-385. PubMed ID: 32879991 [TBL] [Abstract][Full Text] [Related]
3. ADULT HYPOPHOSPHATASIA TREATED WITH TERIPARATIDE: REPORT OF 2 PATIENTS AND REVIEW OF THE LITERATURE. Camacho PM; Mazhari AM; Wilczynski C; Kadanoff R; Mumm S; Whyte MP Endocr Pract; 2016 Aug; 22(8):941-50. PubMed ID: 27042741 [TBL] [Abstract][Full Text] [Related]
4. Biochemical and clinical manifestations in adults with hypophosphatasia: a national cross-sectional study. Hepp N; Frederiksen AL; Duno M; Jørgensen NR; Jensen JB Osteoporos Int; 2022 Dec; 33(12):2595-2605. PubMed ID: 35986118 [TBL] [Abstract][Full Text] [Related]
5. Proposing a clinical algorithm for better diagnosis of hypophosphatasia in resource-limiting situations. Sadhukhan S; Mehta P; Rajender S; Gupta SK; Chattopadhyay N Osteoporos Int; 2022 Dec; 33(12):2479-2493. PubMed ID: 35776147 [TBL] [Abstract][Full Text] [Related]
6. Clinical, radiographic and biochemical characteristics of adult hypophosphatasia. Schmidt T; Mussawy H; Rolvien T; Hawellek T; Hubert J; Rüther W; Amling M; Barvencik F Osteoporos Int; 2017 Sep; 28(9):2653-2662. PubMed ID: 28547134 [TBL] [Abstract][Full Text] [Related]
7. Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia-not atypical at all. Genest F; Seefried L Osteoporos Int; 2018 Aug; 29(8):1815-1825. PubMed ID: 29774402 [TBL] [Abstract][Full Text] [Related]
8. Urine phosphoethanolamine is a specific biomarker for hypophosphatasia in adults. Shajani-Yi Z; Ayala-Lopez N; Black M; Dahir KM Bone; 2022 Oct; 163():116504. PubMed ID: 35878747 [TBL] [Abstract][Full Text] [Related]
9. Dual X-ray absorptiometry has limited utility in detecting bone pathology in children with hypophosphatasia: A pooled post hoc analysis of asfotase alfa clinical trial data. Simmons JH; Rush ET; Petryk A; Zhou S; Martos-Moreno GÁ Bone; 2020 Aug; 137():115413. PubMed ID: 32417537 [TBL] [Abstract][Full Text] [Related]
10. Hypophosphatasia in Adults: Clinical Spectrum and Its Association With Genetics and Metabolic Substrates. Lefever E; Witters P; Gielen E; Vanclooster A; Meersseman W; Morava E; Cassiman D; Laurent MR J Clin Densitom; 2020; 23(3):340-348. PubMed ID: 30655187 [TBL] [Abstract][Full Text] [Related]
11. Hypophosphatasia: Natural history study of 101 affected children investigated at one research center. Whyte MP; Wenkert D; Zhang F Bone; 2016 Dec; 93():125-138. PubMed ID: 27576207 [TBL] [Abstract][Full Text] [Related]
12. Treatment of adult hypophosphatasia with teriparatide. Camacho PM; Painter S; Kadanoff R Endocr Pract; 2008 Mar; 14(2):204-8. PubMed ID: 18308659 [TBL] [Abstract][Full Text] [Related]
13. A low serum alkaline phosphatase may signal hypophosphatasia in osteoporosis clinic patients. Ng E; Ashkar C; Seeman E; Schneider HG; Nguyen H; Ebeling PR; Sztal-Mazer S Osteoporos Int; 2023 Feb; 34(2):327-337. PubMed ID: 36434431 [TBL] [Abstract][Full Text] [Related]
14. Bone turnover and mineral metabolism in adult patients with hypophosphatasia treated with asfotase alfa. Seefried L; Rak D; Petryk A; Genest F Osteoporos Int; 2021 Dec; 32(12):2505-2513. PubMed ID: 34215909 [TBL] [Abstract][Full Text] [Related]
15. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Kishnani PS; Rockman-Greenberg C; Rauch F; Bhatti MT; Moseley S; Denker AE; Watsky E; Whyte MP Bone; 2019 Apr; 121():149-162. PubMed ID: 30576866 [TBL] [Abstract][Full Text] [Related]
16. Biochemical algorithm to identify individuals with ALPL variants among subjects with persistent hypophosphatasaemia. Tornero C; Navarro-Compán V; Buño A; Heath KE; Díaz-Almirón M; Balsa A; Tenorio JA; Quer J; Aguado P Orphanet J Rare Dis; 2022 Mar; 17(1):98. PubMed ID: 35241128 [TBL] [Abstract][Full Text] [Related]
17. Investigation of ALPL variant states and clinical outcomes: An analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa. Kishnani PS; Del Angel G; Zhou S; Rush ET Mol Genet Metab; 2021 May; 133(1):113-121. PubMed ID: 33814268 [TBL] [Abstract][Full Text] [Related]
18. Predictive modeling of hypophosphatasia based on a case series of adult patients with persistent hypophosphatasemia. Garcia-Carretero R; Olid-Velilla M; Perez-Torrella D; Torres-Pacho N; Darnaude-Ortiz MT; Bustamate-Zuloeta AD; Tenorio JA Osteoporos Int; 2021 Sep; 32(9):1815-1824. PubMed ID: 33619648 [TBL] [Abstract][Full Text] [Related]